AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AGMB AgomAb Therapeutics

休市中 07-10 16:00:00 EDT

13.08

+0.05

+0.38%

盘后13.08

+0.000.00%

19:34 EDT

最高13.27	最低12.54	成交量4.72万
今开13.11	昨收13.03	日振幅5.64%
总市值6.44亿	流通市值1.64亿	总股本4,925万
成交额61.09万	换手率0.38%	流通股本1,250万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.08,"timestamp":1783713600000,"preClose":13.03,"halted":0,"volume":47228,"hourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":13.08,"latestTime":"19:34 EDT","volume":15,"amount":198,"timestamp":1783726440949,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003837298541826609,"floatShares":12500000,"shares":49248000,"eps":-1.488082,"marketStatus":"休市中","change":0.05,"latestTime":"07-10 16:00:00 EDT","open":13.11,"high":13.27,"low":12.535,"amount":610906,"amplitude":0.056408,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.488082,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":13.03,"postHourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":13.08,"latestTime":"19:34 EDT","volume":15,"amount":198,"timestamp":1783726440949,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.687153},"requestUrl":"/m/hq/s/AGMB","defaultTab":"news","newsList":[{"id":"1186837702","title":"Agomab公布Ontunisertib治疗纤维狭窄型克罗恩病的新时代2B期研究设计方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1186837702","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186837702?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:06","pubTimestamp":1782245174,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics公司宣布，已为其候选药物Ontunisertib针对纤维狭窄型克罗恩病的治疗，完成了名为“Nov-Era”的2B期临床研究方案设计。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119430627","title":"Leerink Partners首次覆盖AgomAb Therapeutics，给予“跑赢大盘”评级，目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119430627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119430627?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:56","pubTimestamp":1772538974,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布启动对生物技术公司AgomAb Therapeutics（AGMB）的研究覆盖，并给予“跑赢大盘”评级。该机构为该公司设定了36美元的目标股价，显示出对其未来增长潜力的积极预期。\n此次覆盖标志着市场对AgomAb Therapeutics研发管线的关注升温。Leerink Partners的看好评级基于对公司核心技术与业务前景的深入评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129897501","title":"异动解读 | 新股上市遇冷，AgomAb Therapeutics盘中大跌18.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129897501","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129897501?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:54","pubTimestamp":1770400445,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%，引起了市场的广泛关注。消息面上，该公司于周五正式登陆美股市场，但新股表现不佳，开盘即大幅下跌。根据相关报道，其IPO价格为16美元，上市后股价持续走低，市场对其首秀反应冷淡。AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司，专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元，其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607091502","title":"比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091502","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607091502?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:16","pubTimestamp":1769757418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，比利时二期生物科技公司AgomAb Therapeutics于美东时间周四公布了其美股IPO条款。该公司专注于开发针对克罗恩病及其他纤维化疾病的TGFβ抑制剂。按拟议发行价区间中值计算，AgomAb Therapeutics的完全稀释后市值将达到8.75亿美元。AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新疾病修正疗法。AgomAb Therapeutics成立于2017年，计划以股票代码“AGMB”在纳斯达克上市。公司预计将于今年2月完成IPO定价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4539","BK4139","LENZ","BK4585","VT","AGMB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agomab.com","stockEarnings":[{"period":"1week","weight":0.034},{"period":"1month","weight":0.2662},{"period":"3month","weight":0.241},{"period":"6month","weight":-0.1825},{"period":"ytd","weight":-0.1825}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立为比利时私人有限责任公司，并于2019年3月14日转换为比利时有限责任公司。该公司是一家临床阶段的生物制药公司，专注于为存在高度未满足医疗需求的纤维炎症性疾病开发新型疾病修饰疗法。","exchange":"NASDAQ","name":"AgomAb Therapeutics","nameEN":"AgomAb Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AgomAb Therapeutics,AGMB,AgomAb Therapeutics股票,AgomAb Therapeutics股票老虎,AgomAb Therapeutics股票老虎国际,AgomAb Therapeutics行情,AgomAb Therapeutics股票行情,AgomAb Therapeutics股价,AgomAb Therapeutics股市,AgomAb Therapeutics股票价格,AgomAb Therapeutics股票交易,AgomAb Therapeutics股票购买,AgomAb Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}